PROTO-HORMONES LEVELS OF ADIPOSE TISSUE, INTERLEUKIN-6 AND INDICATORS OF DETOXIFYING FUNCTION OF THE LIVER IN PATIENTS WITH HYPERTENSION AND OBESITY COMBINED WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Open Access
- 29 October 2020
- journal article
- Published by OU Scientific Route in Technology transfer: innovative solutions in medicine
Abstract
The research estimates the state of liver detoxifying function and analyzes the changes in the levels of leptin, adiponectin and interleukin-6 in patients with arterial hypertension in combination with obesity and non-alcoholic fatty liver disease. Aim. The aim of the study is to evaluate levels of proto-hormones adipose tissue, interleukin-6 and indicators of detoxifying function of the liver in patients with hypertension and obesity combined with non-alcoholic fatty liver disease (NAFLD). Materials and methods. The study involved patients with arterial hypertension combined with obesity and NAFLD. All patients underwent anthropometric, general clinical, laboratory (blood lipid profile) and instrumental diagnostics (electrocardiography, echocardiography, ultrasonography, 13C-metacetin breath test, ELISA (adiponectin, leptin, IL-6). The patients’ height and weight were measured, the body mass index was calculated according to standard formulas. Results. Patients with arterial hypertension combined with obesity and NAFLD at the stage of steatohepatitis showed an increase in the levels of leptin and IL-6 and a decrease in the level of adiponectin. This group also revealed a moderate decrease in liver detoxifying function, as indicated by the results of 13C- MBT due to a 46.7 % decrease in the metabolic rate and a decrease in cumulative doses of CUM40 by 40 % and CUM120 by 46.8 %, respectively. Conclusions. The elevated levels of leptin and IL-6 and lowered adiponectin levels can be used to determine the degree of activity of non-alcoholic steatohepatitis and predict the course of NAFLD in combination with hypertension and obesity. An increased level of leptin and IL-6 and a low level of adiponectin in patients with such a comorbid pathology lead to an increase in the left ventricular myocardial mass index and aggravate the course of arterial hypertension.Keywords
This publication has 13 references indexed in Scilit:
- Polymorphic analysis of leptin promoter in obese/diabetic subjects in Kashmiri populationIndian Journal of Endocrinology and Metabolism, 2019
- Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple InteractionsInternational Journal of Molecular Sciences, 2017
- Differential Role of Leptin and Adiponectin in Cardiovascular SystemInternational Journal of Endocrinology, 2015
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationJournal of Hepatology, 2012
- Adiponectin Regulation and FunctionPublished by Wiley ,2011
- IL-6 and lipid metabolismInflammation and Regeneration, 2011
- Leptin: The Prototypic Adipocytokine and its Role in NAFLDCurrent Pharmaceutical Design, 2010
- The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism, 2010
- Serum adipokine levels predictive of liver injury in non‐alcoholic fatty liver diseaseLiver International, 2009
- Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST studyVascular Health and Risk Management, 2009